8/12/2025, 10:30:00 AM | www.globenewswire.com | news

Global Veterinary Regenerative Medicine Market Size/Share

The global veterinary regenerative medicine market was valued at USD 401.21 million in 2024 and is projected to reach USD 452.97 million in 2025, with a forecast of USD 1395.44 million by 2034, growing at a CAGR of 13.23% from 2025 to 2034. Growth is driven by demand for minimally invasive, sustainable treatments such as stem cell therapy, platelet-rich plasma (PRP), gene therapy, and tissue engineering for orthopedic, wound healing, and dermatological conditions in companion and livestock animals. Advances in cell culture and autologous therapy kits enable in-house processing in veterinary clinics. Increasing focus on animal welfare, rising veterinary spending, and supportive regulatory frameworks in North America and Europe are accelerating adoption. The market is segmented by product type, application, animal type, and end-user. North America leads in adoption, Europe is research-intensive, and Asia-Pacific shows high growth potential. Key players include VetStem Biopharma, Medrego, Ardent Animal Health, Zoetis, Boehringer Ingelheim Animal Health, Vetherapy, Celavet Inc., Gallant, Animal Cell Therapies Inc., ReGen Medicine, Epona Biotech, StemcellVet, Anicell Biotech, Companion Regenerative Therapies, EquiCord, Smith+Nephew (Veterinary Division), Owl Manor Veterinary, Exceed Equine, Regeneus Ltd., and Cell Therapy Sciences Ltd. Strengths include reduced medication reliance, faster recovery, and improved quality of life. Weaknesses include high costs, inconsistent insurance coverage, and lack of standardization. Opportunities involve expansion into livestock and exotic species, integration with digital diagnostics, and development of off-the-shelf therapies. Threats include competition from traditional treatments, public skepticism, regulatory delays, and market consolidation.